Cargando…

Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy

The appearance of chemoresistance in cancer is a major issue. The main barriers to conventional tumor chemotherapy are undesirable toxic effects and multidrug resistance. Cancer nanotherapeutics were developed to get around the drawbacks of conventional chemotherapy. Through clinical evaluation of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Katopodi, Theodora, Petanidis, Savvas, Tsavlis, Drosos, Anestakis, Doxakis, Charalampidis, Charalampos, Chatziprodromidou, Ioanna, Eskitzis, Panagiotis, Zarogoulidis, Paul, Kosmidis, Christoforos, Matthaios, Dimitris, Porpodis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634039/
https://www.ncbi.nlm.nih.gov/pubmed/36338748
http://dx.doi.org/10.3389/fonc.2022.1042125
_version_ 1784824378857357312
author Katopodi, Theodora
Petanidis, Savvas
Tsavlis, Drosos
Anestakis, Doxakis
Charalampidis, Charalampos
Chatziprodromidou, Ioanna
Eskitzis, Panagiotis
Zarogoulidis, Paul
Kosmidis, Christoforos
Matthaios, Dimitris
Porpodis, Konstantinos
author_facet Katopodi, Theodora
Petanidis, Savvas
Tsavlis, Drosos
Anestakis, Doxakis
Charalampidis, Charalampos
Chatziprodromidou, Ioanna
Eskitzis, Panagiotis
Zarogoulidis, Paul
Kosmidis, Christoforos
Matthaios, Dimitris
Porpodis, Konstantinos
author_sort Katopodi, Theodora
collection PubMed
description The appearance of chemoresistance in cancer is a major issue. The main barriers to conventional tumor chemotherapy are undesirable toxic effects and multidrug resistance. Cancer nanotherapeutics were developed to get around the drawbacks of conventional chemotherapy. Through clinical evaluation of thoughtfully developed nano delivery systems, cancer nanotherapeutics have recently offered unmatched potential to comprehend and combat drug resistance and toxicity. In different design approaches, including passive targeting, active targeting, nanomedicine, and multimodal nanomedicine combination therapy, were successful in treating cancer in this situation. Even though cancer nanotherapy has achieved considerable technological development, tumor biology complexity and heterogeneity and a lack of full knowledge of nano-bio interactions remain important hurdles to future clinical translation and commercialization. The recent developments and advancements in cancer nanotherapeutics utilizing a wide variety of nanomaterial-based platforms to overcome cancer treatment resistance are covered in this article. Additionally, an evaluation of different nanotherapeutics-based approaches to cancer treatment, such as tumor microenvironment targeted techniques, sophisticated delivery methods for the precise targeting of cancer stem cells, as well as an update on clinical studies are discussed. Lastly, the potential for cancer nanotherapeutics to overcome tumor relapse and the therapeutic effects and targeted efficacies of modern nanosystems are analyzed.
format Online
Article
Text
id pubmed-9634039
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96340392022-11-05 Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy Katopodi, Theodora Petanidis, Savvas Tsavlis, Drosos Anestakis, Doxakis Charalampidis, Charalampos Chatziprodromidou, Ioanna Eskitzis, Panagiotis Zarogoulidis, Paul Kosmidis, Christoforos Matthaios, Dimitris Porpodis, Konstantinos Front Oncol Oncology The appearance of chemoresistance in cancer is a major issue. The main barriers to conventional tumor chemotherapy are undesirable toxic effects and multidrug resistance. Cancer nanotherapeutics were developed to get around the drawbacks of conventional chemotherapy. Through clinical evaluation of thoughtfully developed nano delivery systems, cancer nanotherapeutics have recently offered unmatched potential to comprehend and combat drug resistance and toxicity. In different design approaches, including passive targeting, active targeting, nanomedicine, and multimodal nanomedicine combination therapy, were successful in treating cancer in this situation. Even though cancer nanotherapy has achieved considerable technological development, tumor biology complexity and heterogeneity and a lack of full knowledge of nano-bio interactions remain important hurdles to future clinical translation and commercialization. The recent developments and advancements in cancer nanotherapeutics utilizing a wide variety of nanomaterial-based platforms to overcome cancer treatment resistance are covered in this article. Additionally, an evaluation of different nanotherapeutics-based approaches to cancer treatment, such as tumor microenvironment targeted techniques, sophisticated delivery methods for the precise targeting of cancer stem cells, as well as an update on clinical studies are discussed. Lastly, the potential for cancer nanotherapeutics to overcome tumor relapse and the therapeutic effects and targeted efficacies of modern nanosystems are analyzed. Frontiers Media S.A. 2022-10-21 /pmc/articles/PMC9634039/ /pubmed/36338748 http://dx.doi.org/10.3389/fonc.2022.1042125 Text en Copyright © 2022 Katopodi, Petanidis, Tsavlis, Anestakis, Charalampidis, Chatziprodromidou, Eskitzis, Zarogoulidis, Kosmidis, Matthaios and Porpodis https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Katopodi, Theodora
Petanidis, Savvas
Tsavlis, Drosos
Anestakis, Doxakis
Charalampidis, Charalampos
Chatziprodromidou, Ioanna
Eskitzis, Panagiotis
Zarogoulidis, Paul
Kosmidis, Christoforos
Matthaios, Dimitris
Porpodis, Konstantinos
Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy
title Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy
title_full Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy
title_fullStr Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy
title_full_unstemmed Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy
title_short Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy
title_sort engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634039/
https://www.ncbi.nlm.nih.gov/pubmed/36338748
http://dx.doi.org/10.3389/fonc.2022.1042125
work_keys_str_mv AT katopoditheodora engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy
AT petanidissavvas engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy
AT tsavlisdrosos engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy
AT anestakisdoxakis engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy
AT charalampidischaralampos engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy
AT chatziprodromidouioanna engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy
AT eskitzispanagiotis engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy
AT zarogoulidispaul engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy
AT kosmidischristoforos engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy
AT matthaiosdimitris engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy
AT porpodiskonstantinos engineeredmultifunctionalnanocarriersforcontrolleddrugdeliveryintumorimmunotherapy